Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
HIGH-LEVELS OF HIPPOCAMPAL CHOLINERGIC NEUROSTIMULATING PEPTIDE (HCNP) IN THE CSF OF SOME PATIENTS WITH ALZHEIMERS-DISEASE
Autore:
TSUGU Y; OJIKA K; MATSUKAWA N; IWASE T; OTSUKA Y; KATADA E; MITAKE S;
Indirizzi:
NAGOYA CITY UNIV,SCH MED,DEPT INTERNAL MED 2,MIZUHO KU NAGOYA AICHI 4678601 JAPAN NAGOYA CITY UNIV,SCH MED,DEPT INTERNAL MED 2,MIZUHO KU NAGOYA AICHI 4678601 JAPAN
Titolo Testata:
European journal of neurology
fascicolo: 6, volume: 5, anno: 1998,
pagine: 561 - 569
SICI:
1351-5101(1998)5:6<561:HOHCNP>2.0.ZU;2-8
Fonte:
ISI
Lingua:
ENG
Soggetto:
CEREBROSPINAL-FLUID; SENILE DEMENTIA; EARLY-ONSET; PROTEIN-PRECURSOR; BASAL FOREBRAIN; RAT; ACETYLCHOLINESTERASE; SOMATOSTATIN; EXPRESSION; DIAGNOSIS;
Keywords:
ALZHEIMERS DISEASE; CEREBROSPINAL FLUID (CSF); HIPPOCAMPAL CHOLINERGIC NEUROSTIMULATING PEPTIDE; PEPTIDE; CHOLINERGIC NEURON;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
38
Recensione:
Indirizzi per estratti:
Citazione:
Y. Tsugu et al., "HIGH-LEVELS OF HIPPOCAMPAL CHOLINERGIC NEUROSTIMULATING PEPTIDE (HCNP) IN THE CSF OF SOME PATIENTS WITH ALZHEIMERS-DISEASE", European journal of neurology, 5(6), 1998, pp. 561-569

Abstract

Hippocampal cholinergic neurostimulating peptide (HCNP), originally purified from the hippocampus of young rats, enhances the cholinergic development of rat medial septal nuclei in vitro. This report concerns the determination of the HCNP content of the cerebrospinal fluid (CSF)of 173 clinically, and of 22 clinico-pathologically defined patients. A radioimmunoassay was used throughout. The HCNP level was relativelyuniform among the clinically defined patients; for almost all non-Alzheimer's patients, the level fell within the range delimited by +/-2 SD of the mean for all patients taken together, and none of them had a level above this range. By contrast, the early-onset Alzheimer's disease patients could be divided on the basis of their HCNP level into twogroups, one with high levels (markedly above the mean +/-2 SD range),and the other with levels similar to those of the other patients. Theanalysis of the CSF samples obtained postmortem revealed that Group IAlzheimer-type dementia (ATD) patients with clinico-pathologically established diagnoses had a strikingly higher level of HCNP than patients with either Group II ATD or cerebral vascular disease. These resultssuggest that HCNP is involved in certain pathophysiological alterations associated with dementia, and that its determination may be useful in patient evaluation. Eur J Neurol 5:561-569 (C) 1998 Lippincott Williams & Wilkins.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/01/20 alle ore 11:47:37